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Amiodarone side effectsAmiodarone is a potent, iodine rich, highly lipophilic class III antiarrhythmic drug widely used for the manage-
ment of both supraventricular and ventricular arrhythmias. It tends to concentrate in tissues including fat,
lung, liver cornea and skin. Several side effects have been reported in patients taking amiodarone. The mecha-
nisms of amiodarone-induced side effects are poorly understood. Accumulation of amiodarone in tissues and
organs has been suggested as a possible mechanism. The most frequent dermatologic side effects are photosen-
sitivity, skin discoloration and erythema. This article presents the case of a patient who developed amiodarone-
induced bullous skin lesions and hepatotoxicity.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Amiodarone is considered as a class III antiarrythmic (Vaughan
Williams classiﬁcation). It possesses electrophysiologic characteristics
of sodium, potassium and calcium channel blockage, as well as alpha
and beta adrenergic blocking activity.1,2 It is commonly used in the
treatment of supraventricular and ventricular arrhythmias, such as atri-
al ﬁbrillation and ventricular tachycardia.3 It has strong antiarrythmic
properties but may cause neurologic, pulmonary, thyroid, ocular,
dermatologic, and hepatic toxicity in long-term or excessive use. The
mechanisms of side effects are not well understood. The most common
side effects of amiodarone are nausea and vomiting, which occur in
approximately 25% of patients. Side effects of the skin are also common,
occurring in approximately 15% of patients.4 Patients frequently experi-
ence photosensitivity. Other dermatological side effects of amiodarone
include skin discoloration and blue-gray or yellow-brown pigmenta-
tion. In this report, we present a case of ventricular tachycardia
that developed erythematous exudative bullous skin lesions and hepa-
totoxicity during amiodarone therapy.90 474 2251193.
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Sixty-one year old male patient was admitted to the emergency
department with complaints of palpitation, dyspnea and chest pain.
He had the same symptoms twice in the last 24 h. He denied any synco-
pe or dizziness. He had a history of hypertension and a coronary angiog-
raphy which was performed 2 years ago. The angiogram showed slow
ﬂow in the coronary arteries without any other coronary pathology.
The patient was treated with acetylsalicylic acid (ASA) and antihyper-
tensive medications.
The patient had a hemodynamically stable ventricular tachycardia.
The remaining systemic examination was normal.
Electrocardiography (ECG) showed sinus rhythm in leads I–III, aVR,
AVL, and AVF at initial recording. The rest of the ECG revealed mono-
morphic, monofocal ventricular tachycardia (VT). The rhythm on cardi-
acmonitorwas consistentwith VT (Fig. A). Hemogram and biochemical
parameters were within normal limits.
Two-dimensional (2-D) echocardiography was performed after
medical cardioversion and cardiac measurements were determined by
2D, cross sectional Mmode and Doppler study echocardiography. Echo-
cardiographic measurements as follows: right ventricle diameter:
1.9 cm, left ventricular end-diastolic diameter: 4.5 cm, interventricular
septum diastolic diameter: 1.4 cm, and the left ventricular posterior
wall diastolic diameter: 1.2 cm. Left ventricular ejection fraction was
calculated as 58% by using the modiﬁed Simpson technique. There
was no valvular, supravalvular or infravalvular stenosis in the aorta
and pulmonary artery.vier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. A. 12-Lead surface ECG during ventricular tachycardia.
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clinical and hemodynamic parameters itwasdecided that amedical car-
dioversion was required. After loading dose of amiodarone, (150 mg in
100 mL dextrose (D5W) administered over 10 min), the patient was
returned to sinus rhythm. His dyspnea and palpitations disappeared.
The patientwas taken to the coronary care unit and therapywas contin-
ued with a slow loading infusion containing 900 mg amiodarone injec-
tion in 500 mL of dextrose (D5W). The infusion was administered at a
rate of 1 mg/min for 6 h followed by maintenance infusion at a rate of
0.5 mg/min over 18 h.
Coronary angiography revealed ectasia in the proximal andmid por-
tions of the LAD and Cx with no critical obstructive lesions. There was
also slow ﬂow in both coronary arteries.
One day later, the patient had elevated liver enzymes and devel-
oped multiple bullous skin lesions over the anterior chest wall ﬁlled
with exudative material. All bullae appeared on slightly erythema-
tous base. Diameters of the largest and the smallest bulla were
2.3 × 1.5 cm and 0.6 × 0.7 cm respectively. Erythema was more
prominent around the hair follicles and occurred both on the nor-
mal and involved skin (Figs. B and C). The biochemistry and
hemogram results were as follows: Alanine transaminase (ALT)
99 U/L (normal b 41 U/L), aspartate transaminase (AST) 89 U/L
(normal b 40 U/L), lactate dehydrogenase (LDH) 210 U/L (normal
135–225 U/L), monocyte 0.59 c/μL (normal 0.12–1.2 c/μL) and baso-
philes 0.08 c/μL (normal 0.00–0.02 c/μL). The results of other labo-
ratory tests were within normal limits.
Amiodarone was stopped and the patient was started on
propafenone (class Ic antiarrhythmic agent) orally every 12 h. Dur-
ing the follow-up, no VT or other arrhythmia was observed and liver
enzymes returned to normal. He was discharged on the sixth day of
hospitalization with prescriptions of acetylsalicylic acid 100 mg
1 × 1, propafenone 150 mg 2 × 1 and valsartan 160 mg 1 × 1. One
month later, at the follow-up visit, the patient noted that his symp-
toms had subsided. The patient's biochemical, hemogram and ECG
results were normal. Bullae healed leaving scar tissue (Fig. D).Twenty four hour holter monitoring showed no pathological
ﬁndings.
Discussion
Amiodarone is probably one of the most potent antiarrhythmic
medications that we have available. Unfortunately, it also has side
effects; up to 40% of patients quit amiodarone within 2 years due to
those side effects.1,5,6 It is metabolized in the liver by cytochrome
p450 enzymes and excreted in the bile. Less than 1% of the dose excret-
ed in the urine.7 Its main metabolite, desethylamiodarone, has also
multiple side effects.8 The mechanisms of side effects are not fully un-
derstood. Side effects include photosensitivity (25% to 75%), blue-gray
or yellow-brown skin discoloration located mostly on the face, ears,
and palms of the hands (4% to 9%), hepatotoxicity (15% to 30%); optic
neuropathy/neuritis (1% to 2%), corneal microdepsits (N90%), pulmo-
nary toxicity (1% to 17%), hypothyroidism (6%), hyperthyroidism
(0.9% to 2%), tremor and ataxia (3% to 35%).3 Peripheric neuropathy, in-
somnia,memory loss and delirium are uncommon side effects that have
been reported in the literature. Life-threatening anaphylaxis or anaphy-
lactoid reaction, pulmonary alveolitis and ﬁbrosis have been reported.2,9
Our patient had elevated liver enzyme levels and multiple bullae.
Bullae ﬁlled with no purulent ﬂuid resembling exudates. Light micro-
scopic skin examination revealed normal epidermis. The Hematoxylin-
Eosin-Saffron stained sections demonstrated few yellow brown gran-
ules within cytoplasm of histiocytes in the mid dermis. These
pigmented histiocytes clustered around capillaries. Minimal inﬂamma-
tionwas observed. Histochemically the pigmentswere strongly positive
by Ziehl–Neelsen, mild to moderate positive by PAS and negative by
turnbull blue stainings. 10,11
Electron microscopy revealed polygonal to fusiform shaped histio-
cytes with large cytoplasm, dispersed between dermal collagen ﬁbers.
Spheroid and extended nucleolus with dense chromatin network and
large cytoplasm contained dense bodies ranging in size from 250 to
2500 nm, dense granules and eosinophilic materials. No difference
Fig. B.Multiple bullous lesions ﬁlled with material resembling exuda.
Fig. C.Multiple bullous lesions ﬁlled with material resembling exuda.
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mic reticulum and free ribosomes.10,11
Dermatological complications of amiodarone are time-and dose-
dependent. In most cases adverse effects are reversible with discontin-
uation of therapy. The main skin changes induced by amiodarone are
phototoxic and photoallergic reactions, as well as hyperpigmentation.
More than 10% of patients have been reported to have sunlight sensitiv-
ity. The symptoms begin in several minutes after exposure to the sun-
light, continue up to 24 h and usually subside in approximately 48 h,
but in some cases they persist up to 72 h. Phototoxic and photoallergic
reactionsmight even occur a fewmonths after the withdrawal of amio-
darone due to its long elimination time.12 During long-term or high-
dosage amiodarone therapy, patients should be recommended to pro-
tect themselves against photosensitivity. Patients should wear light-
weight clothing that covers most surface areas of skin and use
sunscreen to protect themselves from harmful UV-A/UV-B radiation.3
Blue-gray discoloration of the skin is an uncommon adverse effect
caused by the accumulation of lipofuscin and melatonin in dermis.13
The appearance of the discoloration depends on the dosage of amioda-
rone and duration of use, and may regress upon cessation of the
treatment.14 Biopsy conﬁrms skin impregnation of iodine with deposi-
tion of brown pigment within dermal microphages. Occurrence of skinlesions does not require discontinuation of therapy. Treatment should
be stopped if liver enzyme levels exceed three times the upper limit of
normal.15
The amiodarone molecule contains a large amount of inorganic
iodine, which may exacerbate certain skin diseases, such as dermatitis
herpetiformis and psoriasis. There have been reports of post-
amiodarone pseudo-purulent changes, such as acne or blister-
purulent lesions characteristic of iodism.12,16 Less common dermatolog-
ical complications of amiodarone include hives, pruritus, erythema
nodosum, purpura, and the most severe variant of erythema
multiforme-toxic epidermal necrolysis.17,18
Amiodarone can induce allergic reactions in sensitized patients.
Although themechanisms of allergic reaction to amiodarone are poorly
understood, it is believed to occur due to the 37.3% iodine that is pres-
ent in the amiodarone molecule. The incidence of amiodarone induced
hypersensitivity reactions in hospitalized patients with a listed allergy
to iodine or iodinated contrast agents was found to be 0.4%.19 Physi-
cians should be cautious while prescribing amiodarone for such
patients.Conclusion
Amiodarone is a potent antiarrhythmic agent that is used to treat
ventricular and supraventricular arrhythmias. Side effects due to amio-
darone are related to dosage and route of administration. Skin lesions
are common side effects of amiodarone therapy and do not require
discontinuation of treatment. Treatment should be stopped if patients
develop hepatotoxicity or liver enzyme elevations greater than the tri-
ple normal limit. It should be kept in mind that exudative bullous skin
lesions may occur during amiodarone therapy.
Fig. D. At one month follow-up visit, the patient showed healed bullae with scarring (black arrows).
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